Recent studies have demonstrated that in vivo inosine and its derivatives could inhibit the activity of ubiquitin-activating enzyme 6(UBA6) to increase the immunogenicity of tumor cells, improving the tumor immunotherapy response [23]. This evidence concerns the gene UBA6 and neoplasm.